Welcome to our dedicated page for Akero Therapeutics SEC filings (Ticker: AKRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing efruxifermin (EFX) for metabolic dysfunction-associated steatohepatitis (MASH) and related metabolic liver diseases. These regulatory documents offer detailed insight into Akero’s clinical programs, financial position, risk factors and corporate transactions.
Through its annual reports on Form 10-K and quarterly reports on Form 10-Q, Akero describes its business focus on serious metabolic diseases, outlines the design and objectives of the Phase 3 SYNCHRONY program, and discusses prior Phase 2b HARMONY and SYMMETRY results. Management’s discussion and analysis sections explain research and development spending, including costs associated with large global trials and manufacturing of clinical supplies for potential marketing applications.
Current reports on Form 8-K highlight material events. For example, Akero has filed an 8-K describing its Agreement and Plan of Merger with Novo Nordisk A/S and a wholly owned subsidiary of Novo Nordisk, under which Akero is expected to become a wholly owned subsidiary following stockholder approval and satisfaction of closing conditions. Another 8-K details the voluntary prepayment and termination of a prior loan agreement, providing context on changes in the company’s capital structure and debt obligations. Additional 8-K filings furnish quarterly earnings press releases and other significant updates.
Investors researching insider activity can review Forms 4 referenced in Akero’s proxy materials, which report changes in beneficial ownership by directors and executive officers. When available, proxy statements and related solicitation materials explain executive compensation, governance matters and, in connection with the proposed merger, information relevant to the stockholder vote. Stock Titan’s platform surfaces these filings as they are posted to EDGAR and adds AI-powered summaries to help readers interpret lengthy documents such as 10-Ks, 10-Qs, 8-Ks and proxy statements without having to parse every page manually.
Jonathan Young, Chief Operating Officer of Akero Therapeutics, Inc. (AKRO), reported multiple transactions on 10/01/2025 under a Rule 10b5-1 plan. He acquired 12,500 stock options at an exercise price of $21.10 and exercised options that resulted in ownership of 82,482 common shares in total. On the same date he sold 12,500 common shares via a market sale at a weighted-average price of $21.10 (option acquisition) and separately sold 8,299 shares at a weighted-average price of $47.644 and 4,201 shares at a weighted-average price of $47.984. Following the reported transactions, he directly beneficially owned 196,898 shares. He also holds indirect interests of 20,000 shares each through three irrevocable trusts for his children, which he disclaims as beneficial ownership.
Akero Therapeutics, Inc. voluntarily repaid in full its outstanding debt under a term loan facility with Hercules Capital. On September 23, 2025, the company paid an aggregate $37.6 million, covering all outstanding principal, accrued and unpaid interest, fees, costs and expenses under its Loan and Security Agreement.
Following receipt of this payoff amount, all obligations, covenants, debts and liabilities under the loan were satisfied and discharged, and the Loan Agreement and related documents were terminated, other than the existing warrants. The facility had allowed borrowings of up to $150 million, of which Akero had drawn $35 million at a variable interest rate with a scheduled maturity in March 2027.
Akero Therapeutics insider transaction summary: Chief Scientific Officer Timothy Rolph executed multiple transactions on 09/08/2025 under a Rule 10b5-1 trading plan. The Form 4 reports sales totaling 12,500 common shares (12,466 shares at a weighted-average price of $44.169 and 34 shares at $44.875) and three option-related acquisitions recorded as M(1) exchanges: 7,044 option rights with $21.09 strike, 5,161 option rights with $6.364 strike, and 295 option rights with $28.35 strike. Following the transactions, Rolph beneficially owned 167,124 common shares (direct). The filing notes the options are vested and exercisable and that the trades were effected pursuant to a 10b5-1 plan dated August 12, 2024.
Akero Therapeutics (AKRO) Form 144 filing reports a proposed sale of Common Stock by an insider. The notice lists a broker, J.P. Morgan Securities, and an approximate aggregate market value of the proposed sale at $4,015,800 for 90,000 shares, with an approximate sale date of 09/10/2025 on NASDAQ. The filing details the insider's acquisition history: 478 shares from an ESPP on 06/28/2024, 14,581 shares from RSU vesting on 03/09/2023, and 74,941 shares from a stock option exercise on 09/10/2025. It also discloses recent dispositions: 30,000 shares sold on 07/10/2025 for $1,534,895 and 30,000 shares sold on 08/11/2025 for $1,457,589. The filer represents no undisclosed material adverse information.
Akero Therapeutics insider transactions on 09/02/2025 show Jonathan Young, Chief Operating Officer, exercised stock options and sold an equal number of shares under a Rule 10b5-1 plan. The filing reports an exercise/acquisition of 12,500 shares at $21.10 and sales totaling 12,500 shares executed at weighted-average prices of $45.776, $47.136 and $47.58. After these transactions Mr. Young beneficially owned 197,484 shares direct and additionally has three irrevocable trusts holding 20,000 shares each, which he disclaims as beneficial ownership. The transactions were effected pursuant to a 10b5-1 trading plan dated April 29, 2025.
Scott A. Gangloff, Chief Technology Officer of Akero Therapeutics (AKRO), reported a securities transaction dated 08/15/2025. The filing shows an acquisition of 2,600 shares/options with a reported price of $19.62, increasing the reporting person’s beneficial ownership to 26,351 shares following the transaction.
The filing also discloses a derivative position: a stock option with a $19.62 exercise price covering 20,384 underlying common shares, of which 17,784 derivative securities are reported as beneficially owned. The option vests 25% on April 29, 2025, with the balance vesting in 36 equal monthly installments, subject to continued service. The form is signed by an attorney-in-fact on 08/19/2025.
Janus Henderson Group plc reported beneficial ownership of 6,738,556 ordinary shares of Akero Therapeutics, representing 8.5% of the class, and disclosed shared voting and dispositive power over those shares while reporting no sole voting or dispositive power.
The filing also states that JHIUS may be deemed the beneficial owner of 6,654,976 shares (8.4%) and identifies JHIUS, JHIUKL and JHIAIFML as indirect subsidiaries that are registered investment advisers advising Managed Portfolios. Janus Henderson certifies these holdings are held in the ordinary course of business and were not acquired to change or influence control.
RTW Investments, LP and Roderick Wong reported beneficial ownership of 5,873,308 shares of Akero Therapeutics, representing 7.3% of the outstanding common stock. The ownership is reported as shared voting and shared dispositive power, with no sole voting or dispositive power recorded.
The percentage is calculated using 79,717,570 shares outstanding as reported by the company. The filing is an amendment to a Schedule 13G and discloses that the RTW Funds hold the right to receive dividends or sale proceeds on the reported shares.
Jonathan Young, Chief Operating Officer of Akero Therapeutics (AKRO), filed a Form 4 reporting transactions dated 08/12/2025. The filing shows transactions effected pursuant to a Rule 10b5-1 trading plan dated April 29, 2025. The report records an acquisition of 12,500 common shares (and concomitant acquisition of 12,500 stock option rights with an exercise/conversion price of $21.10) and two sales totaling 12,500 shares sold at weighted-average prices of $47.721 and $48.324, respectively.
Following the reported activity the filing lists 197,484 shares beneficially owned directly and derivative holdings of 69,982 option-related instruments. The filing discloses three irrevocable trusts each holding 20,000 shares for the benefit of the reporting person’s children and states the reporting person disclaims beneficial ownership of those trust shares. The option referenced vests in 48 equal monthly installments commencing December 8, 2021.
Akero Therapeutics insider sale by CEO and director Andrew Cheng. The Form 4 reports that Mr. Cheng, who serves as President and CEO and is a company director, executed sales of common stock on 08/11/2025 pursuant to a Rule 10b5-1 trading plan dated August 16, 2024. The filing lists three dispositions of 10,795, 18,805 and 400 shares, each shown as sales, with weighted-average price ranges disclosed in the footnotes.
The footnotes state the shares were sold in multiple transactions at prices ranging $47.40–$48.39, $48.41–$49.39, and $49.43–$49.44, respectively. The report also shows the amount of common stock beneficially owned following the reported transactions as 509,962, 491,157 and 490,757 shares on the corresponding lines. The Form 4 is signed by an attorney-in-fact and identifies the trades as executed under the 10b5-1 plan; no other financial or operational data is included.